AstraZeneca (Alexion) Acquires Amolyt Pharma for Up to $1.05 Billion

Alexion, AstraZeneca Rare Disease Acquires LogicBio Therapeutics

November 16, 2022

Biotechnology

Alexion, AstraZeneca Rare Disease completed its acquisition of LogicBio Therapeutics, a genomic medicine company. The transaction was implemented via a cash tender offer and subsequent merger, with LogicBio continuing as a wholly owned subsidiary of Alexion.

Amgen Completes Acquisition of Horizon Therapeutics plc

October 6, 2023

Biotechnology

Amgen completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, valuing the transaction equity at approximately $27.8 billion. The deal expands Amgen’s inflammation and rare-disease portfolio by adding Horizon’s first-in-class, early-in-lifecycle medicines such as TEPEZZA, KRYSTEXXA, and UPLIZNA.

AstraZeneca Acquires Fusion Pharmaceuticals

March 19, 2024

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage company developing next-generation actinium-based radioconjugates, for $21.00 per share in cash plus a non-transferable contingent value right that could bring the total to approximately $2.4 billion. The acquisition adds Fusion's pipeline (including FPI-2265 for mCRPC), R&D and manufacturing capabilities in radioconjugates and strengthens AstraZeneca's oncology portfolio and presence in Canada.

AstraZeneca to Acquire EsoBiotec

March 18, 2025

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company developing in vivo cell therapies. The deal is valued at up to $1 billion on a cash and debt-free basis, with an initial $425 million payment upon closing plus up to $575 million in contingent milestone consideration. The transaction is expected to close in Q2 2025, subject to regulatory approvals.

Ipsen Acquires Albireo Pharma

January 9, 2023

Biotechnology

Ipsen has agreed to acquire Albireo Pharma in a cash tender offer of $42.00 per share plus a contingent value right (CVR) tied to FDA approval in biliary atresia, in a transaction intended to expand Ipsen's Rare Disease portfolio. The acquisition brings Albireo's approved pediatric liver drug Bylvay (odevixibat) and a pipeline of bile-acid modulators into Ipsen's global R&D and commercial capabilities.

Amgen Acquires ChemoCentryx

August 4, 2022

Biotechnology

Amgen agreed to acquire ChemoCentryx for $52 per share in cash (approximately $3.7 billion enterprise value), gaining TAVNEOS (avacopan), a first-in-class oral therapy for ANCA-associated vasculitis. The deal, unanimously approved by both boards, is intended to strengthen Amgen's inflammation and nephrology portfolio and is expected to close following stockholder and regulatory approvals.